Vanda Pharmaceuticals Inc.
VNDA
$3.87
-$0.055-1.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -500.45% | 7.74% | -17.84% | -8.97% | -72.75% |
| Total Depreciation and Amortization | 0.51% | 0.31% | -0.05% | -11.51% | 92.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,021.29% | 125.52% | -773.62% | -90.65% | 147.33% |
| Change in Net Operating Assets | -366.57% | 107.45% | -109.00% | -166.11% | 147.45% |
| Cash from Operations | -1,724.27% | 87.54% | -110.46% | -191.53% | 302.81% |
| Capital Expenditure | -103.74% | -32.92% | 90.13% | 39.82% | 97.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 953.91% | -65.57% | 189.64% | 12.10% | -127.14% |
| Cash from Investing | 999.47% | -66.88% | 179.00% | 16.23% | 58.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -163.87% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -754.19% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 124.26% | -397.06% | 553.33% | -7.14% | -109.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 421.17% | 174.06% | 88.94% | -108.24% | 77.49% |